Navigation Links
PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
Date:3/6/2008

ANNAPOLIS, Md., March 6 /PRNewswire-FirstCall/ -- PharmAthene, Inc., a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced today that it has completed the initial pharmacokinetic (PK) testing of Protexia(R), the Company's broad spectrum chemical nerve agent prophylaxis.

The PK studies were conducted in two animal species and used the final pegylated version of rBChE for the first time. In general, the conjugation of proteins with polyethylene glycol (PEG) has been shown to decrease immunogenicity, increase circulating serum half-life and increase stability of recombinant proteins. The data from these studies confirm that the specific PEG chosen for conjugation to rBChE will significantly improve the half-life of the protein in vivo.

The PK studies demonstrated that Protexia(R) had a half life of approximately four days in primates and three days in rodents when administered by intramuscular injection. These data compare favorably with what was predicted for the drug's PK profile in these animal species.

John Troyer, Ph.D., Senior Program Director for Protexia(R), commented, "These results are very meaningful in that they show that Protexia(R) meets or exceeds our target product profile for use as a chemical nerve agent prophylaxis. The impressive half life data also confirm that the pegylation of rBChE as part of our manufacturing process achieved the goal of extending the half-life of the protein to one which makes it a feasible product for use in humans."

Dr. Troyer continued, "Having successfully completed the PK studies, we are on target to complete our toxicology studies and file the Investigational New Drug (IND) application for Protexia(R) in the third quarter of 2008; we expect to commence Phase I human safety testing of Protexia(R) in the fourth quarter."

"Today's announcement highlights the intense commitment and stro
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
6. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
7. H2Diesel Completes 3 Million Gallon Per Year Pilot Facility
8. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Carrington Completes $8 Million Financing
11. Proteon Therapeutics Completes $12 Million Financing and Hires CFO

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... SHANGHAI, Dec. 1 /PRNewswire-Asia/ -- Shangha...Pharma, a leading China-based Contract Research,Or...f the 2009 Deloitte,Technology Fast 50 China, rank...ch companies in China. The award is a testament to...th from 2006 to 2008. , The results of th...
(Date:12/1/2009)..., SPRINGFIELD, Ill., Dec. 1 Prair... announce that it was recently awarded two statuet... on Nov. 13 in New York City. The CLIO Healthcare ...on in the healthcare advertising industry and is a... most recognized awards competitions for advertisi...
(Date:12/1/2009)... Enterprise level storage is now avai...ers without breaking the bank. , .... ( www.pacsdrive.com ), a medical imaging softw...compatible cloud storage service. The PacsDrive se...roviders to securely archive medical imaging in co...
(Date:12/1/2009)... Congruent Software agrees to migrate...oject accounting clients) to Synergy Business Solu... Seattle, WA (PRWEB) December 1, 2009 -...s acquired the Microsoft Dynamics SL practice of C...ogy provider. The move was necessary due to a chan...
Breaking Biology Technology:Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies 2Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies 3Prairie Heart Institute of Illinois Wins Two CLIO Healthcare Awards 2PacsDrive Announces Low Cost Medical Imaging Storage Service, Seeks to Alter Status Quo in Health Care IT 2Synergy Business Solutions Acquires the Microsoft Dynamics SL Practice of Congruent Software, Inc. 2Synergy Business Solutions Acquires the Microsoft Dynamics SL Practice of Congruent Software, Inc. 3
...daq: VICL ) presentation at the UBS Global Life S....m. Eastern Daylight Time, will be available by,li... http://www.vical.com ., About Vical, Vical res...sed on its,patented DNA delivery technologies for ...reatening diseases. Potential applications of the,...
...gnificant partial onset seizure reduction, pro... - Keppra XR(TM) is built on a trusted heritage, ...mation:,UCB announced today that the U.S. Food and...TM) (levetiracetam extended-release tablets) for u...for people with partial-onset,seizures who are 16 ...
...n Deficit Hyperactivity ...nual ,ADHD Experts on,Call, program will take plac... midnight EDT to provide families and caregivers o...sorder (ADHD), as well as adults with,ADHD, with t...ut ADHD from,experts in the field. Celebrity desig...
Other Biology Technology:Vical to Present at UBS Global Life Sciences Conference 2Video: Keppra XR(TM) Approved in the U.S. 2Video: Keppra XR(TM) Approved in the U.S. 3Video: Keppra XR(TM) Approved in the U.S. 4Celebrity Designer Ty Pennington to Host 10th Annual 'ADHD Experts on Call' Program 2Celebrity Designer Ty Pennington to Host 10th Annual 'ADHD Experts on Call' Program 3Celebrity Designer Ty Pennington to Host 10th Annual 'ADHD Experts on Call' Program 4Celebrity Designer Ty Pennington to Host 10th Annual 'ADHD Experts on Call' Program 5Celebrity Designer Ty Pennington to Host 10th Annual 'ADHD Experts on Call' Program 6
(Date:12/2/2009)... about a nanometer in diameterhave been highly tou... fibers, electrical wires in molecular devices, or...s to a new development by researchers at the Natio...nd five partners, you can add one more application...essive form of breast cancer. , HER2 is one of a...
(Date:12/2/2009)...y of Southampton,s School of Ocean and Earth Scien...thampton (NOCS) has formally described four new sp...l discovered the new species in the Smithsonian Co...y in Washington. Explaining the significance of th...largest crustaceans currently inhabiting Earth and...
(Date:12/1/2009)...esearch Center, Emory University, have successfull... important step toward unlocking the genetic secre...s technology will enable scientists to perform a h...fy the brain mechanisms of social bonding and othe...lso have important implications for understanding ...
Breaking Biology News(10 mins):Combining nanotubes and antibodies for breast cancer 'search and destroy' missions 2King crab family bigger than ever 2Yerkes researchers create first transgenic prairie voles 2Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 1Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 2Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 3Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 4Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 5Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 6Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 7Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 8Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 9Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 10Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 11Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 12Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 13Cardium Reports Positive Data From Matrix Phase 2b Study of Excellarate 28TM 29 Topical Gel for Non Healing Diabetic Foot Ulcers and Plans for Phase 3 59445 14Webcast Alert 3A Usinas Siderurgicas de Minas Gerais S A USIMINAS Announces Third Quarter 2009 Results Webcast 59442 1Webcast Alert 3A Usinas Siderurgicas de Minas Gerais S A USIMINAS Announces Third Quarter 2009 Results Webcast 59442 2Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 1Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 2Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 3Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 4Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 5Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 6Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 7Cardium Announces Commercial Development of Excellagen 28TM 29 a Customized Collagen Based Topical Gel for Initial Use as an Adjunct to Surgical Debri 59439 8
...searchers have long suspected that fertilizer runo... marine algae capable of disrupting ocean ecosyste... a new study by Stanford University scientists pre...e coastal farming to massive algal blooms in the s...l Nature, the authors conclude that some highly pr...
... one time, scientists wondered whether life existe... kinds of creatures, they wondered, could withstan...nvironment? , Researchers at Scripps Institution ...an Diego, and their colleagues have used innovatio...urate portrayal of deep sea life forms and how the...
...e simple marine sponge is inspiring cutting-edge r...ersity of California, Santa Barbara. , A report a...of gold nanoparticles is the cover story of the cu...terials. The article is written by Daniel E. Morse...al biology at UCSB, and director of the Institute ...
Other Biology News:Oceans more vulnerable to agricultural runoff than previously thought, study finds 2Oceans more vulnerable to agricultural runoff than previously thought, study finds 3Oceans more vulnerable to agricultural runoff than previously thought, study finds 4Advancements In Genomics Foster Deep Sea Discoveries 2Marine sponge yields nanoscale secrets 2Marine sponge yields nanoscale secrets 3
GC-RICH PCR System from Roche Applied Science
GC-RICH PCR System from Roche Applied Science
BD Laminin 60 mm Culture Dishes from BD Biosciences - Discovery Labware
BD BioCoat Collagen I 60 mm Culture Dishes from BD Biosciences - Discovery Labware
Biology Products: